PSKH1 Antibody

What is PSKH1 and why is it important to study?

PSKH1 (Protein Serine Kinase H1) is classified as an understudied or "dark" kinase that has recently gained attention for its critical biological functions. This kinase has been identified as a crucial factor in kidney development and has been found to be overexpressed in prostate, lung, and kidney cancers, suggesting its potential role in oncogenesis . Recent research has causatively linked the loss of PSKH1 kinase activity to kidney ciliopathies in human patients, supporting earlier findings of its involvement in heart cilia organization in mice . Furthermore, PSKH1 appears to function as a splicing factor compartment-associated serine kinase (SFC-associated serine kinase) with a potential role in intranuclear SR protein trafficking and pre-mRNA processing . The emerging importance of PSKH1 in multiple cellular processes and disease states makes it a valuable target for antibody-based research applications aimed at understanding its regulation, localization, and function.

What are the primary cellular localizations of PSKH1?

PSKH1 exhibits a complex subcellular distribution pattern that reflects its diverse cellular functions. According to recent research, PSKH1 is primarily localized in the Brefeldin A-sensitive Golgi compartment, suggesting its involvement in protein trafficking and post-translational modifications . The protein is also found at centrosomes, indicating a potential role in cell division and organization . Within the nucleus, PSKH1 displays a somewhat speckle-like presence, consistent with its proposed function in pre-mRNA processing and splicing regulation . Additionally, PSKH1 can be membrane-associated, with connections to both the endoplasmic reticulum (ER) and the plasma membrane (PM), as well as diffusely distributed throughout the cytoplasm . This multi-compartmental localization pattern presents both challenges and opportunities for antibody-based detection methods, as researchers must ensure their selected antibodies can effectively recognize PSKH1 in these various cellular contexts without cross-reactivity with similar proteins in these locations.

What are the common aliases for PSKH1 that may appear in literature?

When conducting literature searches or designing experiments targeting PSKH1, researchers should be aware of several alternative names used to describe this protein. The protein aliases include Protein serine kinase H1, PSK-H1, Serine/threonine-protein kinase H1, and Mutant line 1230 . At the gene level, PSKH1 may be referred to by gene aliases including AW539964, b2b1230Clo, and E130013P03Rik in mouse studies . In database searches, researchers can use the UniProt IDs P11801 (Human) and Q91YA2 (Mouse), or the Entrez Gene IDs 5681 (Human) and 244631 (Mouse) . Being familiar with these alternative designations is crucial for comprehensive literature searches and for ensuring appropriate antibody selection, as some antibodies may be labeled using these alternative nomenclatures rather than the standard PSKH1 designation.

What factors should be considered when selecting a PSKH1 antibody for research?

When selecting a PSKH1 antibody for research applications, several critical factors must be carefully evaluated to ensure experimental success. First, researchers should consider the specific application requirements, as different techniques (immunofluorescence, Western blotting, immunoprecipitation, etc.) may require antibodies with different characteristics and validation profiles . The species reactivity is another essential consideration; for example, the Thermo Fisher PSKH1 polyclonal antibody shows predicted reactivity with mouse (96% homology), Xenopus laevis (80%), chicken (81%), rhesus monkey (99%), and bovine (95%) PSKH1 proteins, making it suitable for cross-species studies . The epitope recognition is equally important, as antibodies targeting different regions of PSKH1 may yield varying results, especially if post-translational modifications or protein interactions obscure certain epitopes. Additionally, researchers should evaluate the antibody's validation data, including positive controls (such as 293T, A431, HeLa, and HepG2 cell lines for some commercial antibodies) , and any available knockout validation to ensure specificity. Finally, considering the complex subcellular localization of PSKH1, researchers should select antibodies specifically validated for detecting the protein in their compartment of interest.

How can I validate the specificity of a PSKH1 antibody?

Validating the specificity of a PSKH1 antibody is a crucial step in ensuring reliable experimental results, especially considering PSKH1's classification as an understudied kinase. A comprehensive validation approach should include multiple complementary methods. First, researchers should perform Western blot analysis using positive control cell lines known to express PSKH1, such as 293T, A431, HeLa, and HepG2 cells, confirming a single band of the expected molecular weight (approximately 48 kDa) . For more rigorous validation, comparing wild-type samples with PSKH1 knockout or knockdown samples via siRNA or CRISPR-Cas9 techniques can definitively confirm antibody specificity. Immunofluorescence studies should be conducted to verify that the staining pattern matches the expected subcellular localization of PSKH1 in the Golgi, centrosomes, nuclear speckles, ER, and plasma membrane . Peptide competition assays, where the antibody is pre-incubated with the immunizing peptide, can further confirm specificity as this should abolish legitimate signal. Lastly, for advanced validation, immunoprecipitation followed by mass spectrometry analysis can verify that the antibody enriches for PSKH1 and its known interacting partners, such as Calmodulin, Reticulocalbin-3, and UNC119B, as identified in recent studies .

What are the different types of PSKH1 antibodies available for research?

Researchers have several types of PSKH1 antibodies at their disposal, each with distinct advantages for specific applications. Polyclonal antibodies, such as the Thermo Fisher PSKH1 Polyclonal Antibody (PA5-85311), recognize multiple epitopes on the PSKH1 protein, potentially providing stronger signals but with increased risk of cross-reactivity . These antibodies are often preferred for immunoprecipitation and immunofluorescence applications due to their high sensitivity. Monoclonal antibodies, conversely, bind to a single epitope with high specificity, making them valuable for applications where distinguishing between closely related proteins or specific protein states is crucial. Some specialized PSKH1 antibodies are designed to recognize specific post-translational modifications, which can be essential for studying PSKH1 regulation by calcium-dependent processes, as recently elucidated . For research involving protein-protein interactions, conformation-specific antibodies that recognize PSKH1 in its active or inactive conformational states may be available. Additionally, some companies offer recombinant antibodies produced through controlled expression systems, ensuring lot-to-lot consistency and reducing the ethical concerns associated with animal-derived antibodies.

How can PSKH1 antibodies be used in immunofluorescence studies?

PSKH1 antibodies have proven valuable for immunofluorescence studies aiming to elucidate the protein's complex subcellular distribution pattern. When performing immunofluorescence with PSKH1 antibodies, researchers should first optimize fixation methods, as PSKH1's diverse localizations may require specific approaches; paraformaldehyde fixation (4%) for 15-20 minutes at room temperature is typically effective for preserving PSKH1's structure while maintaining accessibility of epitopes . Permeabilization with 0.1-0.2% Triton X-100 is generally suitable for accessing intracellular PSKH1, though gentler detergents like saponin (0.1%) may better preserve Golgi structures where PSKH1 is prominently located. To confirm specificity of PSKH1 staining, co-localization studies with established markers should be performed: GM130 for Golgi localization, pericentrin for centrosomal localization, SC35 for nuclear speckles, calnexin for ER association, and appropriate plasma membrane markers . For advanced applications, researchers can combine PSKH1 immunofluorescence with proximity ligation assays (PLA) to visualize interactions with binding partners like Calmodulin, Reticulocalbin-3, or UNC119B in situ, providing spatial context to biochemical interaction data . Additionally, super-resolution microscopy techniques such as STED or STORM can provide enhanced resolution of PSKH1's precise localization within these subcellular compartments.

What protocols are recommended for using PSKH1 antibodies in Western blot analyses?

For optimal Western blot detection of PSKH1, researchers should follow a carefully optimized protocol that accounts for the protein's properties and expression levels. Sample preparation should include an appropriate lysis buffer containing phosphatase inhibitors (such as sodium orthovanadate, sodium fluoride, and β-glycerophosphate) to preserve PSKH1's phosphorylation state, which may affect antibody recognition . When separating proteins, 10-12% SDS-PAGE gels typically provide good resolution for PSKH1, which has a molecular weight of approximately 48 kDa. After transfer to nitrocellulose or PVDF membranes (the latter often providing better results for PSKH1 detection), blocking with 5% non-fat dry milk or 3-5% BSA in TBST for 1 hour at room temperature is recommended. Primary antibody incubation should be performed at a dilution optimized for the specific antibody (typically 1:500 to 1:2000) in blocking buffer overnight at 4°C, followed by thorough washing and appropriate secondary antibody incubation . For enhanced detection sensitivity, particularly in samples with low PSKH1 expression, signal amplification systems or longer exposure times with ECL substrates may be necessary. Positive controls such as lysates from 293T, A431, HeLa, or HepG2 cells should be included to confirm successful detection . For studies investigating PSKH1 regulation by calcium, researchers may need to prepare samples under specific calcium concentration conditions to capture relevant protein states.

How can PSKH1 antibodies be utilized for immunoprecipitation and protein interaction studies?

PSKH1 antibodies serve as powerful tools for immunoprecipitation (IP) experiments aimed at investigating protein interactions and post-translational modifications. When performing PSKH1 IP, researchers should begin with careful lysis buffer selection; a buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40 or 0.5% Triton X-100, supplemented with protease and phosphatase inhibitors, generally maintains PSKH1 integrity and protein-protein interactions . Pre-clearing the lysate with protein A/G beads reduces non-specific binding, after which the PSKH1 antibody (typically 2-5 μg per mg of total protein) should be added and incubated at 4°C overnight with gentle rotation. The antibody-antigen complexes can then be captured using protein A/G beads and subjected to thorough washing to remove non-specific interactions. For studying PSKH1's kinase activity directly from immunoprecipitates, researchers can employ in vitro kinase assays with radiolabeled ATP and synthetic peptide substrates, such as ADR1 (LKKLTRRASFSGQ), which has been validated as a PSKH1 substrate . To investigate PSKH1's interactions with calcium sensor proteins like Calmodulin or Reticulocalbin-3, co-immunoprecipitation experiments can be performed under varying calcium concentrations to modulate these calcium-dependent interactions . For more comprehensive interaction analysis, PSKH1 immunoprecipitation followed by mass spectrometry provides an unbiased approach to identify novel binding partners, as demonstrated in recent studies that revealed interactions with secretory network proteins .

Why might I be getting weak or no signal when using PSKH1 antibodies?

Several factors could contribute to weak or absent PSKH1 signal in antibody-based experiments. First, consider the expression level of PSKH1 in your sample, as this kinase may have tissue-specific or condition-dependent expression patterns; using positive control samples from cell lines known to express PSKH1, such as 293T, A431, HeLa, or HepG2, can help establish whether the issue lies with the sample or the detection method . The antibody concentration is another critical factor, and titration experiments should be performed to determine the optimal concentration, which may differ from the manufacturer's recommendations depending on your specific application and sample type. Epitope accessibility could be compromised by fixation methods (for immunofluorescence) or denaturation conditions (for Western blotting), so optimizing these parameters may improve signal strength. For immunofluorescence specifically, PSKH1's complex subcellular localization pattern, including association with the Golgi apparatus, centrosomes, nuclear speckles, ER, and plasma membrane, might require specialized fixation and permeabilization protocols to preserve structure while enabling antibody access . Additionally, calcium levels can modulate PSKH1's interactions and potentially its conformation, which might affect epitope recognition; experimentally controlling calcium conditions or using calcium chelators may help resolve this issue . Finally, post-translational modifications of PSKH1, which are still being characterized, might mask epitopes or alter antibody binding, particularly for antibodies targeting regions containing modification sites.

How can I address cross-reactivity issues with PSKH1 antibodies?

Cross-reactivity is a common challenge when working with antibodies against understudied proteins like PSKH1, particularly given its membership in the CAMK kinase family with structurally similar domains. To address potential cross-reactivity issues, researchers should first rigorously validate their PSKH1 antibody using genetic approaches. Ideally, this would involve comparing signals between wild-type samples and those with PSKH1 knockout or knockdown via CRISPR-Cas9 or siRNA techniques; any persistent signal in knockout/knockdown samples indicates cross-reactivity with other proteins . Peptide competition assays can also help distinguish specific from non-specific signals, as pre-incubation with the immunizing peptide should abolish specific PSKH1 recognition while leaving cross-reactive signals intact. When cross-reactivity is confirmed, researchers might need to explore alternative antibodies targeting different epitopes or clones with demonstrated specificity. For Western blot applications, more stringent washing conditions or higher concentrations of blocking agents may reduce non-specific binding, though these modifications risk reducing specific signal as well. In immunofluorescence studies, potential cross-reactivity with PSKH1's paralog, PSKH2, should be carefully considered and evaluated, though recent research suggests these proteins do not heterodimerize under basal conditions . For the most challenging applications requiring absolute specificity, researchers might consider generating their own monoclonal antibodies or employing alternative approaches such as epitope tagging of PSKH1 for detection via highly specific anti-tag antibodies.

What are common pitfalls in PSKH1 immunoprecipitation experiments?

Immunoprecipitation (IP) of PSKH1 presents several technical challenges that researchers should anticipate and address. One major pitfall is insufficient solubilization of PSKH1 from membrane compartments, as this protein is associated with multiple cellular locations including the Golgi, ER, and plasma membrane . To overcome this, lysis buffers containing appropriate detergents (such as 1% NP-40, 0.5% Triton X-100, or 0.5% DDM for membrane-associated fractions) should be optimized, with more stringent detergents potentially required for complete extraction while balancing preservation of protein-protein interactions. Another common issue is co-immunoprecipitation of heat shock proteins, particularly HSP90 and the kinase cochaperone Cdc37, which have been observed to bind PSKH1 ; while these may represent legitimate interactions, they could mask other less abundant binding partners in downstream analyses. PSKH1's interactions with calcium sensor proteins introduce another layer of complexity, as these interactions are calcium-dependent ; researchers must carefully control calcium levels during IP procedures (with either calcium supplementation or chelation) depending on whether they want to preserve or disrupt these interactions. For studies involving kinase activity of immunoprecipitated PSKH1, maintaining the protein in its active conformation is crucial, which may require special buffer conditions and handling to prevent denaturation or inappropriate post-translational modifications. Finally, the choice of antibody for IP is critical, as not all PSKH1 antibodies perform equally well in this application; validation with known PSKH1 interactors like Calmodulin, Reticulocalbin-3, or UNC119B can confirm successful IP of functionally relevant PSKH1 complexes .

How can PSKH1 antibodies be used to study its role in disease models?

PSKH1 antibodies serve as essential tools in investigating this kinase's involvement in various disease states, particularly in cancer and ciliopathies. For cancer research, PSKH1 antibodies can be employed in immunohistochemistry analyses of patient tumor samples to correlate expression levels with clinical outcomes, especially in prostate, lung, and kidney cancers where PSKH1 overexpression has been documented . In xenograft mouse models, PSKH1 antibody-based tissue staining can track changes in expression, localization, and activation state during tumor progression or in response to experimental therapeutics. For investigating PSKH1's newly established role in ciliopathies, immunofluorescence with specialized PSKH1 antibodies can visualize the protein's association with ciliary structures in kidney and other tissues, while co-staining with ciliary markers like acetylated tubulin provides contextual information about ciliary integrity . Particularly promising is the application of PSKH1 antibodies in studies of the novel hepatorenal ciliopathy phenotype recently linked to PSKH1 variants, where immunofluorescence and biochemical analyses can determine how these mutations affect protein localization, stability, and function . For mechanistic insights, proximity labeling approaches combined with PSKH1 antibodies for validation can map the protein's interactome in disease-relevant contexts, potentially revealing dysregulated signaling networks. Additionally, phospho-specific PSKH1 antibodies, though still being developed, could identify activation patterns in pathological states, providing valuable biomarkers for disease progression or treatment response.

How can PSKH1 antibodies be combined with advanced microscopy techniques?

Combining PSKH1 antibodies with cutting-edge microscopy approaches offers unprecedented insights into this kinase's dynamic behavior and functional interactions. Super-resolution microscopy techniques such as Structured Illumination Microscopy (SIM), Stimulated Emission Depletion (STED), or Single-Molecule Localization Microscopy (SMLM) can be employed with PSKH1 antibodies to precisely map its nanoscale organization within the Golgi apparatus, centrosomes, and nuclear speckles, revealing potentially distinct subpopulations within these compartments . Live-cell imaging can be achieved by combining PSKH1 antibody fragments (Fabs) with cell-penetrating peptides or by expressing intrabodies against PSKH1, enabling real-time tracking of its trafficking between cellular compartments and response to calcium fluctuations that regulate its activity . For studying protein-protein interactions in situ, PSKH1 antibodies can be used in Förster Resonance Energy Transfer (FRET) or Fluorescence Lifetime Imaging Microscopy (FLIM) experiments with secondary antibodies against interaction partners like Calmodulin or UNC119B, providing spatial information about where in the cell these regulatory interactions occur . Advanced correlative light and electron microscopy (CLEM) with PSKH1 immunolabeling can bridge the resolution gap between light microscopy and ultrastructural analysis, revealing PSKH1's precise localization relative to cellular ultrastructures. Furthermore, expansion microscopy protocols compatible with PSKH1 immunofluorescence can physically enlarge specimens to achieve super-resolution imaging on conventional microscopes, making advanced PSKH1 visualization more accessible to researchers without specialized equipment.

What approaches can be used to study PSKH1 phosphorylation substrates with antibody-based methods?

The identification and validation of PSKH1 phosphorylation substrates represent critical aspects of understanding this kinase's cellular functions, with antibody-based approaches offering several powerful strategies. Phospho-specific antibodies against the PSKH1 consensus motif, recently defined through positional scanning peptide array analysis as preferring basic residues at the -3 position and hydrophobic residues at the +1 position, can be used to detect potential substrates in cell lysates before and after PSKH1 manipulation . For substrate validation, researchers can combine PSKH1 immunoprecipitation with in vitro kinase assays using candidate proteins, followed by phospho-specific antibody detection or mass spectrometry to confirm direct phosphorylation. The Kinase-Associated Substrate Screening (KASS) method, which involves PSKH1 overexpression followed by phosphoproteomic analysis with subsequent validation using phospho-motif antibodies, can identify novel substrates on a proteome-wide scale. For studying PSKH1's potential role in pre-mRNA processing, antibodies against SR proteins (splicing regulators) can be used in co-immunoprecipitation studies with PSKH1, followed by phosphorylation site analysis to establish these factors as direct substrates . Additionally, proximity-dependent labeling approaches like TurboID or BioID fused to PSKH1, combined with phosphoproteomics and antibody validation, can identify substrates within specific subcellular compartments where PSKH1 resides . For temporal dynamics of substrate phosphorylation, especially in response to calcium fluctuations that regulate PSKH1 activity, researchers can employ time-course experiments with phospho-specific antibodies following calcium ionophore treatment or physiological calcium signaling events.

How are PSKH1 antibodies being used to investigate calcium-dependent regulation?

PSKH1 antibodies are becoming instrumental in deciphering the complex calcium-dependent regulatory mechanisms of this kinase, particularly following recent discoveries about its interactions with calcium sensor proteins. Researchers are employing co-immunoprecipitation with PSKH1 antibodies under varying calcium concentrations to capture dynamic interaction profiles with calcium sensors like Calmodulin, which activates PSKH1, and Reticulocalbin-3 of the CREC family, which suppresses PSKH1 activity . These studies are complemented by proximity ligation assays (PLA) using paired PSKH1 and calcium sensor antibodies to visualize these interactions in situ and map their subcellular distribution. To understand the structural basis of these calcium-dependent interactions, chemical crosslinking mass spectrometry approaches combined with PSKH1 immunoprecipitation are being utilized to identify specific binding interfaces between PSKH1 and its calcium-sensing regulators . For functional studies, PSKH1 antibodies are being used to immunoprecipitate the kinase for in vitro activity assays with recombinant Calmodulin or CREC family proteins in the presence of varying calcium concentrations, directly measuring how these interactions modulate PSKH1's catalytic activity toward substrates like the ADR1 peptide . Additionally, phospho-specific antibodies against PSKH1 autophosphorylation sites are being developed to monitor activation states in response to calcium fluctuations in cells, providing a readout of endogenous PSKH1 activity. These multifaceted approaches with PSKH1 antibodies are helping to establish a comprehensive model of how extremes in calcium flux can be decoded to tune PSKH1 kinase activity in various cellular contexts.

What is known about PSKH1's role in ciliopathies and how are antibodies advancing this research?

Recent discoveries have established PSKH1 as a critical player in ciliopathy disorders, with antibody-based research significantly advancing our understanding of its mechanistic contributions. PSKH1 antibodies are being utilized for immunohistochemistry and immunofluorescence studies in patient-derived samples from individuals with kidney ciliopathies, allowing researchers to visualize changes in PSKH1 localization, abundance, or post-translational modifications associated with disease-causing mutations . In animal models of ciliopathies, PSKH1 antibody staining is revealing the protein's specific localization relative to ciliary structures and its potential functional interactions with other ciliopathy-associated proteins. Particularly significant is the application of PSKH1 antibodies in studying a recently identified novel hepatorenal ciliopathy phenotype associated with PSKH1 variants, where four families shared distinct PSKH1 mutations . In these cases, antibody-based analyses are helping to determine whether these mutations affect protein stability, localization to centrosomes or cilia, or catalytic activity. For functional studies, PSKH1 antibodies combined with proximity labeling approaches are mapping the protein's interactome specifically within ciliary and centrosomal compartments, identifying potential ciliopathy-relevant interaction partners. Additionally, phosphoproteomics studies from PSKH1 immunoprecipitates are discovering ciliary substrates of this kinase, providing mechanistic insights into how its activity maintains ciliary structure and function. As this research field evolves, PSKH1 antibodies with enhanced specificity for different conformational states or post-translational modifications will be crucial for understanding the molecular basis of PSKH1-associated ciliopathies and potentially developing targeted therapeutic approaches.

How might PSKH1 antibodies contribute to cancer research and potential therapeutic development?

PSKH1 antibodies are emerging as valuable tools in cancer research, particularly given the documented overexpression of this kinase in prostate, lung, and kidney cancers . Researchers are employing PSKH1 antibodies for immunohistochemical analysis of tumor microarrays to establish correlations between expression levels and clinicopathological parameters, potentially identifying PSKH1 as a prognostic biomarker. For mechanistic investigations, PSKH1 antibodies are being used in co-immunoprecipitation studies from cancer cell lines to identify cancer-specific interaction partners that might promote oncogenic signaling or confer therapeutic vulnerabilities. Phosphoproteomic analyses of PSKH1 immunoprecipitates from normal versus cancer cells are revealing differential substrate targeting, providing insights into how this kinase might contribute to malignant transformation or progression. In functional studies, antibody-based detection of PSKH1 is being combined with cell proliferation, migration, and invasion assays following PSKH1 knockdown or inhibition, establishing direct links between this kinase's activity and cancer cell behaviors. From a therapeutic perspective, PSKH1 antibodies conjugated to fluorophores or nanoparticles are being explored for cancer imaging applications, particularly in tumors with PSKH1 overexpression. Looking toward therapeutic development, researchers are utilizing structural information gleaned from antibody epitope mapping to design small molecule inhibitors targeting PSKH1's catalytic site or allosteric regulatory interfaces with Calmodulin or UNC119B . Additionally, the recent elucidation of PSKH1's substrate consensus motif using peptide array analysis provides a foundation for developing substrate-competitive inhibitors, with antibodies serving as crucial tools for validating target engagement and efficacy in preclinical models . As this field advances, increasingly specific PSKH1 antibodies will be essential for patient stratification in potential clinical trials targeting this kinase.